Phase 3 Study to Evaluate Investigational Drug, XEN1101, in Patients with Primary Generalized Tonic-Clonic Seizures: XPF-010-303
Official Title
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Purpose
In this research study a study drug named XEN1101 is being tested for the treatment of seizures. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use. People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and includes up to 7 in-person visits.
Could this study be right for you?
1. Experiencing at least 3 PGTCS in an 8-week period
2. Have tried at least 2 anti-seizure medications without success
3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 12 months
4. 18 years old and up